Review

proc glm command (SAS institute)

SAS institute is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

SAS institute proc glm command

A Insulin sensitivity pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in insulin sensitivity in AZD4017+prednisolone and placebo+prednisolone groups. C Glucose disposal pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in glucose disposal in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. M/I value (Low insulin) AZD4017 + prednisolone n = 15, M/I value (Low insulin) placebo+prednisolone n = 15, Glucose disposal (Low insulin) AZD4017 + prednisolone n = 14, Glucose disposal (Low insulin) placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo + prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 2A, <t>generalised</t> <t>linear</t> <t>models</t> adjusting for baseline variability in each specified outcome; Fig. 2B and D and paired two-tailed t-test; Fig. 2C.

Proc Glm Command, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proc glm command/product/SAS institute
Average 90 stars, based on 1 article reviews

proc glm command - by Bioz Stars, 2026-04

90/100 stars

Images

1) Product Images from "11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial"

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

Journal: Nature Communications

doi: 10.1038/s41467-023-36541-w

Figure Legend Snippet: A Insulin sensitivity pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in insulin sensitivity in AZD4017+prednisolone and placebo+prednisolone groups. C Glucose disposal pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in glucose disposal in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. M/I value (Low insulin) AZD4017 + prednisolone n = 15, M/I value (Low insulin) placebo+prednisolone n = 15, Glucose disposal (Low insulin) AZD4017 + prednisolone n = 14, Glucose disposal (Low insulin) placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo + prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 2A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 2B and D and paired two-tailed t-test; Fig. 2C.

Techniques Used: Two Tailed Test

A Circulating TAG levels pre and post treatment in the AZD4017+prednisolone group. B Circulating TAG levels pre and post treatment in the placebo+prednisolone group. C Change in circulating TAG levels in AZD4017+prednisolone and placebo+prednisolone groups. D Circulating glycerol levels pre and post treatment in the AZD4017+prednisolone group. E Circulating glycerol levels pre and post treatment in the placebo+prednisolone group. F Change in circulating glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. G Adipose interstitial fluid glycerol levels pre and post treatment in the AZD4017+prednisolone group. H Adipose interstitial fluid glycerol levels pre and post treatment in the placebo+prednisolone group. I Change in adipose interstitial fluid glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. Subcutaneous adipose tissue interstitial fluid glycerol levels were increased by placebo + prednisolone treatment, but not when prednisolone was combined with AZD4017 ( G – I ). Data are medians, and error bars are IQR ( A – F , I ) and mean and SD ( G , H ). Data points represent individual patients ( A – F , I ) Circulating TAG AZD4017 + prednisolone: n = 15, Circulating TAG placebo + prednisolone: n = 15, Circulating Glycerol AZD4017 + prednisolone: n = 15, Circulating Glycerol placebo+prednisolone: Basal; n = 15, Low insulin; n = 15, High insulin; n = 14, Adipose interstitial fluid Glycerol AZD4017 + prednisolone: Basal; n = 12, Low insulin; n = 11, High insulin; n = 12, Adipose interstitial fluid Glycerol placebo + prednisolone: Basal; n = 13, Low insulin; n = 13, High insulin; n = 12, (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 3A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 3 B, D and I and paired two-tailed t-test; Fig. 3C.

Figure Legend Snippet: A Circulating TAG levels pre and post treatment in the AZD4017+prednisolone group. B Circulating TAG levels pre and post treatment in the placebo+prednisolone group. C Change in circulating TAG levels in AZD4017+prednisolone and placebo+prednisolone groups. D Circulating glycerol levels pre and post treatment in the AZD4017+prednisolone group. E Circulating glycerol levels pre and post treatment in the placebo+prednisolone group. F Change in circulating glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. G Adipose interstitial fluid glycerol levels pre and post treatment in the AZD4017+prednisolone group. H Adipose interstitial fluid glycerol levels pre and post treatment in the placebo+prednisolone group. I Change in adipose interstitial fluid glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. Subcutaneous adipose tissue interstitial fluid glycerol levels were increased by placebo + prednisolone treatment, but not when prednisolone was combined with AZD4017 ( G – I ). Data are medians, and error bars are IQR ( A – F , I ) and mean and SD ( G , H ). Data points represent individual patients ( A – F , I ) Circulating TAG AZD4017 + prednisolone: n = 15, Circulating TAG placebo + prednisolone: n = 15, Circulating Glycerol AZD4017 + prednisolone: n = 15, Circulating Glycerol placebo+prednisolone: Basal; n = 15, Low insulin; n = 15, High insulin; n = 14, Adipose interstitial fluid Glycerol AZD4017 + prednisolone: Basal; n = 12, Low insulin; n = 11, High insulin; n = 12, Adipose interstitial fluid Glycerol placebo + prednisolone: Basal; n = 13, Low insulin; n = 13, High insulin; n = 12, (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 3A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 3 B, D and I and paired two-tailed t-test; Fig. 3C.

Techniques Used: Two Tailed Test

A Night-time diastolic blood pressure pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in night-time diastolic blood pressure in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 13, placebo+prednisolone n = 14. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 4A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 4B.

Figure Legend Snippet: A Night-time diastolic blood pressure pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in night-time diastolic blood pressure in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 13, placebo+prednisolone n = 14. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 4A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 4B.

Techniques Used:

A Serum osteocalcin levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in serum osteocalcin levels in AZD4017+prednisolone and placebo+prednisolone groups. C Serum P1NP levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in serum P1NP levels in AZD4017+prednisolone and placebo+prednisolone groups. E Serum CTX levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. F Change in serum CTX levels in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 5A, paired two-tailed t-test; Fig. 5C and E and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 5B, D and F.

Figure Legend Snippet: A Serum osteocalcin levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in serum osteocalcin levels in AZD4017+prednisolone and placebo+prednisolone groups. C Serum P1NP levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in serum P1NP levels in AZD4017+prednisolone and placebo+prednisolone groups. E Serum CTX levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. F Change in serum CTX levels in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 5A, paired two-tailed t-test; Fig. 5C and E and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 5B, D and F.

Techniques Used: Two Tailed Test

A OX40 PHA levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in OX40 PHA levels in AZD4017+prednisolone and placebo+prednisolone groups. C OX40 VZV levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in OX40 VZV levels in AZD4017+prednisolone and placebo+prednisolone groups. Changes in glucocorticoid responsive circulating cytokines following treatment with placebo+prednisolone vs. AZD4017 + prednisolone ( E ). Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 6A and c, and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 6B and D.

Figure Legend Snippet: A OX40 PHA levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in OX40 PHA levels in AZD4017+prednisolone and placebo+prednisolone groups. C OX40 VZV levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in OX40 VZV levels in AZD4017+prednisolone and placebo+prednisolone groups. Changes in glucocorticoid responsive circulating cytokines following treatment with placebo+prednisolone vs. AZD4017 + prednisolone ( E ). Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 6A and c, and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 6B and D.

Techniques Used:

Image Search Results

Journal: Nature Communications

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

doi: 10.1038/s41467-023-36541-w

Figure Lengend Snippet: A Insulin sensitivity pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in insulin sensitivity in AZD4017+prednisolone and placebo+prednisolone groups. C Glucose disposal pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in glucose disposal in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. M/I value (Low insulin) AZD4017 + prednisolone n = 15, M/I value (Low insulin) placebo+prednisolone n = 15, Glucose disposal (Low insulin) AZD4017 + prednisolone n = 14, Glucose disposal (Low insulin) placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo + prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 2A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 2B and D and paired two-tailed t-test; Fig. 2C.

Techniques: Two Tailed Test

Journal: Nature Communications

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

doi: 10.1038/s41467-023-36541-w

Figure Lengend Snippet: A Circulating TAG levels pre and post treatment in the AZD4017+prednisolone group. B Circulating TAG levels pre and post treatment in the placebo+prednisolone group. C Change in circulating TAG levels in AZD4017+prednisolone and placebo+prednisolone groups. D Circulating glycerol levels pre and post treatment in the AZD4017+prednisolone group. E Circulating glycerol levels pre and post treatment in the placebo+prednisolone group. F Change in circulating glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. G Adipose interstitial fluid glycerol levels pre and post treatment in the AZD4017+prednisolone group. H Adipose interstitial fluid glycerol levels pre and post treatment in the placebo+prednisolone group. I Change in adipose interstitial fluid glycerol levels in AZD4017+prednisolone and placebo+prednisolone groups. Subcutaneous adipose tissue interstitial fluid glycerol levels were increased by placebo + prednisolone treatment, but not when prednisolone was combined with AZD4017 ( G – I ). Data are medians, and error bars are IQR ( A – F , I ) and mean and SD ( G , H ). Data points represent individual patients ( A – F , I ) Circulating TAG AZD4017 + prednisolone: n = 15, Circulating TAG placebo + prednisolone: n = 15, Circulating Glycerol AZD4017 + prednisolone: n = 15, Circulating Glycerol placebo+prednisolone: Basal; n = 15, Low insulin; n = 15, High insulin; n = 14, Adipose interstitial fluid Glycerol AZD4017 + prednisolone: Basal; n = 12, Low insulin; n = 11, High insulin; n = 12, Adipose interstitial fluid Glycerol placebo + prednisolone: Basal; n = 13, Low insulin; n = 13, High insulin; n = 12, (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo + prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 3A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 3 B, D and I and paired two-tailed t-test; Fig. 3C.

Techniques: Two Tailed Test

Journal: Nature Communications

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

doi: 10.1038/s41467-023-36541-w

Figure Lengend Snippet: A Night-time diastolic blood pressure pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in night-time diastolic blood pressure in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 13, placebo+prednisolone n = 14. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 4A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 4B.

Techniques:

Journal: Nature Communications

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

doi: 10.1038/s41467-023-36541-w

Figure Lengend Snippet: A Serum osteocalcin levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in serum osteocalcin levels in AZD4017+prednisolone and placebo+prednisolone groups. C Serum P1NP levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in serum P1NP levels in AZD4017+prednisolone and placebo+prednisolone groups. E Serum CTX levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. F Change in serum CTX levels in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 5A, paired two-tailed t-test; Fig. 5C and E and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 5B, D and F.

Techniques: Two Tailed Test

Journal: Nature Communications

Article Title: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

doi: 10.1038/s41467-023-36541-w

Figure Lengend Snippet: A OX40 PHA levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in OX40 PHA levels in AZD4017+prednisolone and placebo+prednisolone groups. C OX40 VZV levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in OX40 VZV levels in AZD4017+prednisolone and placebo+prednisolone groups. Changes in glucocorticoid responsive circulating cytokines following treatment with placebo+prednisolone vs. AZD4017 + prednisolone ( E ). Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 6A and c, and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 6B and D.

Techniques:

Review

Structured Review

Images

1) Product Images from "11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial"

Similar Products

Image Search Results